Tags

Type your tag names separated by a space and hit enter

Decreased bone resorption with soy isoflavone supplementation in postmenopausal women.

Abstract

OBJECTIVE

To investigate the effect of soy isoflavone supplementation on bone mineral density (BMD) and markers of bone turnover in postmenopausal women.

METHODS

In this randomized, placebo-controlled clinical trial, we used a crossover design to test the effect of soy isoflavone (110 mg/day) (1.3:1.0:0.22 ratio of genistein/daidzein/ glycitein) on bone formation, bone resorption, bone mineral content (BMC), and BMD for 6 months.

RESULTS

Postmenopausal women (n = 19), mean age 70.6 +/- 6.3 years and mean time since menopause 19.1 +/- 5.5 years, were given isoflavone supplements for 6 months. There was a 37% decrease in urinary concentrations of type 1 collagen alpha1-chain helical peptide (HP), a marker of bone resorption, during the isoflavone supplementation compared with baseline (p < 0.05) and a significant difference in mean (SE) HP excretion levels when isoflavone was compared with placebo (43.4 +/- 5.2 vs. 56.3 +/- 7.2 microg/mmol creatinine [cr], p < 0.05). With isoflavone supplementation, mean spine BMD at L2 and L3 was significantly greater when treatment was compared with control, with a difference between means of 0.03 +/- 0.04 g and 0.03 +/- 0.04 g (p < 0.05), respectively. There were nonsignificant increases from baseline for total spine BMC (3.5%), total spine BMD (1%), total hip BMC (3.6%), and total hip BMD (1.3%) with the isoflavone treatment.

CONCLUSIONS

Soy isoflavone, in isolated form, was effective in this study to significantly decrease bone resorption in postmenopausal women. Further investigation needs to be done to evaluate the long-term effects of soy isoflavone on bone mass and fracture risk.

Authors+Show Affiliations

,

Case Western Reserve University, Cleveland, Ohio 44109, USA. lharkness@metrohealth.org

, , ,

Source

Journal of women's health (2002) 13:9 2004 Nov pg 1000-7

MeSH

Aged
Aged, 80 and over
Biomarkers
Bone Density
Bone Resorption
Cross-Over Studies
Double-Blind Method
Female
Humans
Isoflavones
Middle Aged
Osteoporosis, Postmenopausal
Postmenopause
Risk Factors
Soybean Proteins
Time Factors
Treatment Outcome

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

15665657

Citation

Harkness, Laura S., et al. "Decreased Bone Resorption With Soy Isoflavone Supplementation in Postmenopausal Women." Journal of Women's Health (2002), vol. 13, no. 9, 2004, pp. 1000-7.
Harkness LS, Fiedler K, Sehgal AR, et al. Decreased bone resorption with soy isoflavone supplementation in postmenopausal women. J Womens Health (Larchmt). 2004;13(9):1000-7.
Harkness, L. S., Fiedler, K., Sehgal, A. R., Oravec, D., & Lerner, E. (2004). Decreased bone resorption with soy isoflavone supplementation in postmenopausal women. Journal of Women's Health (2002), 13(9), pp. 1000-7.
Harkness LS, et al. Decreased Bone Resorption With Soy Isoflavone Supplementation in Postmenopausal Women. J Womens Health (Larchmt). 2004;13(9):1000-7. PubMed PMID: 15665657.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Decreased bone resorption with soy isoflavone supplementation in postmenopausal women. AU - Harkness,Laura S, AU - Fiedler,Karen, AU - Sehgal,Ashwini R, AU - Oravec,Dubravka, AU - Lerner,Edith, PY - 2005/1/25/pubmed PY - 2005/3/5/medline PY - 2005/1/25/entrez SP - 1000 EP - 7 JF - Journal of women's health (2002) JO - J Womens Health (Larchmt) VL - 13 IS - 9 N2 - OBJECTIVE: To investigate the effect of soy isoflavone supplementation on bone mineral density (BMD) and markers of bone turnover in postmenopausal women. METHODS: In this randomized, placebo-controlled clinical trial, we used a crossover design to test the effect of soy isoflavone (110 mg/day) (1.3:1.0:0.22 ratio of genistein/daidzein/ glycitein) on bone formation, bone resorption, bone mineral content (BMC), and BMD for 6 months. RESULTS: Postmenopausal women (n = 19), mean age 70.6 +/- 6.3 years and mean time since menopause 19.1 +/- 5.5 years, were given isoflavone supplements for 6 months. There was a 37% decrease in urinary concentrations of type 1 collagen alpha1-chain helical peptide (HP), a marker of bone resorption, during the isoflavone supplementation compared with baseline (p < 0.05) and a significant difference in mean (SE) HP excretion levels when isoflavone was compared with placebo (43.4 +/- 5.2 vs. 56.3 +/- 7.2 microg/mmol creatinine [cr], p < 0.05). With isoflavone supplementation, mean spine BMD at L2 and L3 was significantly greater when treatment was compared with control, with a difference between means of 0.03 +/- 0.04 g and 0.03 +/- 0.04 g (p < 0.05), respectively. There were nonsignificant increases from baseline for total spine BMC (3.5%), total spine BMD (1%), total hip BMC (3.6%), and total hip BMD (1.3%) with the isoflavone treatment. CONCLUSIONS: Soy isoflavone, in isolated form, was effective in this study to significantly decrease bone resorption in postmenopausal women. Further investigation needs to be done to evaluate the long-term effects of soy isoflavone on bone mass and fracture risk. SN - 1540-9996 UR - https://www.unboundmedicine.com/medline/citation/15665657/Decreased_bone_resorption_with_soy_isoflavone_supplementation_in_postmenopausal_women_ L2 - https://medlineplus.gov/bonedensity.html DB - PRIME DP - Unbound Medicine ER -